Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients. 

The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients. 

Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."

“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”

Sanofi will also cut the price of short-acting Apidra by 70 percent.

Share:
More In Business
Orange Juice Prices on the Rise
Prices for wholesale orange juice rose to the highest point on Tuesday due to low inventory and harvesting issues in the U.S.
Stretching Your Dollar: What Thanksgiving Food Prices Could Look Like
As the holiday season nears and with families making plans for Thanksgiving at the end of the month, concerns about high food prices linger. Dr. Michael Swanson, chief agricultural economist with Wells Fargo Agri-Food Institute, joined Cheddar News to provide tips on what to expect when shopping for those large family meals.
Load More